Advertisement
Screener

RENOVORX, INC. (RNXT) EBITDA

RENOVORX, INC. (RNXT) EBITDA

  • 2026-06-30: Basis Reported; EBITDA (m); Operating income -$3.35M; Depreciation and amortization (m).
  • 2026-03-31: Basis Reported; EBITDA (m); Operating income -$3.47M; Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA (m); Operating income -$3.20M; Depreciation and amortization (m).
  • 2025-06-30: Basis Reported; EBITDA (m); Operating income -$2.68M; Depreciation and amortization (m).

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported(m)-$3.35M(m)(m)(m)$71.00K*-$2.87M*(m)$1.20M$2.92M$0.00*
2026-03-31Reported(m)-$3.47M(m)(m)(m)$0.00-$3.71M(m)$1.23M$2.72M$0.00
2025-09-30Reported(m)-$3.20M(m)(m)(m)$0.00*-$2.27M*(m)$1.69M$1.73M$0.00*
2025-06-30Reported(m)-$2.68M(m)(m)(m)$0.00*-$2.30M*(m)$1.43M$1.52M$0.00*
2025-03-31Reported(m)-$3.11M(m)(m)(m)$2.00K-$3.38M(m)$1.64M$1.57M$0.00
2024-09-30Reported(m)-$2.83M(m)(m)(m)(m)-$2.19M*(m)$1.65M$1.18M$0.00*
2024-06-30Reported(m)-$3.03M(m)(m)(m)(m)-$2.30M*(m)$1.54M$1.49M$0.00*
2024-03-31Reported(m)-$2.48M(m)(m)(m)(m)-$2.20M(m)$1.26M$1.22M$0.00
2023-09-30Reported(m)-$2.98M(m)(m)(m)(m)-$2.73M*(m)$1.63M(m)(m)
2023-06-30Reported(m)-$3.38M(m)(m)(m)(m)-$2.77M*(m)$1.93M(m)(m)
2023-03-31Reported(m)-$3.26M(m)(m)(m)(m)-$2.71M(m)$1.34M(m)(m)
2022-09-30Reported(m)-$2.16M(m)(m)(m)(m)-$2.67M*(m)$846.00K(m)(m)
2022-06-30Reported(m)-$2.61M(m)(m)(m)(m)-$2.36M*(m)$1.39M(m)(m)
2022-03-31Reported(m)-$3.00M(m)(m)(m)(m)-$2.10M(m)$1.29M(m)(m)
2021-09-30Reported(m)-$1.40M(m)(m)(m)(m)-$1.12M*(m)$767.00K(m)(m)
2021-06-30Reported(m)-$866.00K(m)(m)(m)(m)-$1.25M*(m)$536.00K(m)(m)
2021-03-31Reported(m)-$1.05M(m)(m)(m)(m)-$992.00K(m)$635.00K(m)(m)
2020-09-30Reported(m)-$910.00K(m)(m)(m)(m)(m)(m)$727.00K(m)(m)

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported(m)-$12.51M(m)(m)(m)$2.00K-$10.97M(m)$6.27M$7.04M$2.00K
2024-12-31Reported(m)-$10.97M(m)(m)(m)$12.00K-$9.13M(m)$6.03M$4.99M(m)
2023-12-31Reported(m)-$11.40M(m)(m)(m)(m)-$10.26M(m)$5.67M$5.73M(m)
2022-12-31Reported(m)-$9.95M(m)(m)(m)(m)-$8.81M(m)$4.30M(m)(m)
2021-12-31Reported(m)-$5.67M(m)(m)(m)(m)-$5.92M(m)$3.04M(m)(m)
2020-12-31Reported(m)-$3.20M(m)(m)(m)(m)-$3.53M(m)$2.39M(m)(m)

Similar stocks

Stock NameCountryMarket CapPE Ratio
FRACTYL HEALTH, INC. (GUTS)United States$0.075B-1.18
Pulmonx Corp (LUNG)United States$0.082B-1.16
CVRx, Inc. (CVRX)United States$0.067B-2.62
SkinHealth Systems Inc. (SKIN)United States$0.086B-3.17
DarioHealth Corp. (DRIO)$0.066B-1.39
LENSAR, Inc. (LNSR)United States$0.087B2.02
Microbot Medical Inc. (MBOT)$0.089B-7.97
TELA Bio, Inc. (TELA)United States$0.057B-0.82
Xtant Medical Holdings, Inc. (XTNT)United States$0.053B
Spectral AI, Inc. (MDAI)United States$0.052B